Cell and gene therapies present tremendous clinical and humanistic opportunity to change the course of disease but also present several unique aspects that differ from more traditional therapies. These differences will impact how innovators develop evidence and manufacture and distribute products. Payers also need to adapt how they assess value, make coverage decisions, and manage reimbursement.
Join us for the webinar Oncology Care in a Value-Based World which will highlight the activities and needs of payers and providers as they strive to deliver high-quality oncology care in a value-based environment. In this presentation, KOLs with market access, population health, and EMR experience will share the ways in which payers and health systems are supporting a value-based approach to oncology through care initiatives, technology, and access to innovative therapies.
In the first part of our Trends webinar series, our experts discussed how this shift has facilitated novel collaboration between health systems, plans, and pharmaceutical manufacturers and has also led to many new opportunities--but how is the healthcare landscape responding? Join us to learn how new clinical and scientific innovations are shifting the healthcare paradigm.
Join Precision experts Ross Maclean, Dominic Galante and Maureen Hennessey as they offer insights into trends that are gaining velocity. Watch "Beyond the First 100 Days: Healthcare Policy and Value-Based Care Trends That You Need to Know" on-demand today.
Join us for a webinar featuring KOLs emphasizing applied learnings in the SDOH and population health fields.
Congratulations to Precision Medicine Group Co-Founder and CEO Mark Clein on his moderated Point: Counterpoint panel at this year’s HLTH Conference.
A deep dive into the future of biosimilars: In this In this exclusive 2-part video interview for AJMC's Center for Biosimilars, editor Matthew Gavidia speaks with PRECISIONvalue's Ryan Cox to discuss what employers can do to encourage biosimilar uptake, the cultural changes that are needed to make it happen, and whether midsize employers can participate in payer discussions on formulary placement.
In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers.
As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. Watch this on-demand webinar and Q&A moderated by Precision's Larry Blandford, as we explore these challenges, and discuss solutions to getting innovative therapies into the hands of patients who need them most.
Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Moderated by Precision's Kelly Wilder, join us and learn how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
